A pharmacokinetic evaluation of moxalactam was performed with 30 infants and children with documented or suspected bacterial infections arising outside the central nervous system. Each child received 50 mg of moxalactam per kg infused intravenously over a period of 15 min every 8 h. A total of 26 children were studied after receiving the first dose; 20 of these, along with 4 additional patients, were evaluated after receiving continuous therapy for at least 3 days. After the first dose, the elimination half-life, apparent volume of distribution, and plasma clearance averaged 1.59 h, 0.331 liter/kg, and 100.9 ml/min per 1.73 m2, respec- tively. The biodisposition of the moxalactam epimers was also evaluated, with similar overall results. No differences in pharmacokinetic parameters were observed when the first-dose values were compared with those obtained at the steady state. Age-dependent changes in moxalactam elimination were observed for children of s1 year of age, suggesting that a dosage reduction may be necessary for children of c2 months of age.
Moxalactam is a 1-oxa-,B-lactam possessing a broad spectrum of antibacterial activity (2, 11, 16). Recent studies of both adult (4, 8) and pediatric (5, 6, 12, 15) patients have demonstrated the efficacy of the drug in the management of a variety of acute and chronic infections. However, despite the antimicrobial efficacy of moxalactam, rational dosing recommendations for the treatment of serious infections in infants and children are lacking.
To date, moxalactam dosing in these patients has been largely empiric. Pharmacokinetic evaluations of children have been limited and primarily involve first-dose evaluations; The purpose of the present investigation was to describe the first-dose and steady-state pharmacokinetics of moxalactam in seriously ill infants and children. Such an analysis should permit the development of rational dosing recommendations for moxalactam in this patient population.
( Venous blood samples (minimum, 0.5 ml) for the determination of moxalactam in serum and for pharmacokinetic evaluation were obtained at 0, 0.25, 0.5, 1, 2, 3, 6, and 8 h after the beginning of the infusion. Blood was collected in sterile glass tubes, allowed to clot on ice, and immediately centrifuged. Serum was removed and stored at -70°C until analyzed.
Concentrations of moxalactam in serum were determined by high-pressure liquid chromatography after protein precipitation with methanol (9). Chromatography was performed on an MCH 10 column, using a mobile phase consisting of 5% acetonitrile-95% of 0.09 M ammonium citrate (pH 6.5) flowing at 1 ml/min. The column temperature was maintained at 30°C with a heater block, and the effluent was monitored at 270 nm. Under these conditions, the limit of moxalactam detectability was 2 p.g/ml, with a linear range of up to 400 ,g/ml. The between-day coefficients of variation for the sum of the epimers at 200 and 20 ,ug/ml were 3.1 and 10.7%, respectively. (Cl) were observed between the Cl of moxalactam and ae j ssing a one-compartn*nt pharmacokinetic age. In children of <1 year of age, the Cl of by the -method of Sawcbuck and Zaske (13) and moxalactam correlated directly (r = 0.883; P < tuck et al. (14) . Statistical analysis was per-0.01) with age (Fig. 2) . Figure 2C depicts (Fig. 2B) but was a result of irty patients rnging in age from 7 days to the age-related increase in the elimination of years were studied. A total of 26 patients moxalactam ( Fig. 2A) . Interestingly, a negative evaluated after receiving the first dose, and correlation (r = -0.372; P < 0.05) was observed "these patients were reevaluatod after re-between the Vd and age for the entire group of ig the drug every 8 h for at least 3 days. An patients. 
DISCUSSION
The results of the present investigation revealed only minimal differences between the first-dose and the steady-state pharmacokinetics of moxalactam and its epimers in infants and children (Table 1) . When moxalactam biodisposition in children of <1 year of age was compared with that observed in children of >1 year of age, the serum t1j2 was found to be significantly prolonged (P < 0.05), and the Cl was significantly reduced (P < 0.05).
The relationship of tj/2, Cl, and Vd in children of s1 year is shown in Fig. 2 . The immaturity and variation in renal excretory development (7) are reflected by the reduced Cl and prolonged tj/2 during the first 2 months of life. After 2 months of age and as renal function matures, Cl increases and tj/2 decreases logarithmically to values observed with older infants and children. This significant inverse relationship between tj/2 and age (P < 0.05) for these infants is in agreement with the data of Schaad et al. (15) and is further supported by the positive relationship of Cl or Kd and age (P < 0.05; Table 2 ).
In children of <1 year of age, the Vd of moxalactam was larger than that observed in older children (Table 2 ). This reduction in the Vd of moxalactam in children of -1 year of age was most likely a result of the developmental changes observed with age in total body water content of neonates and infants (3). The variation observed in the Vd of moxalactam may also have been a result of the effects of the underlying disease state which has been reported with other drugs in adults but which has not been adequately evaluated in children (18) .
Moxalactam is a mixture of R and S epimers: 52.6% R and 47.4% S. The pharmacokinetic evaluation of the R and S epimers is shown in Table 1 . The tj,2 was slightly longer and the Vd and Cl were reduced for the S epimer as compared with the R epimer. Nahata et al. reported similar differences between the R and S epimers after a single dose of moxalactam in 12 infants and children ranging in age from 10 months to 3.8 years (10). However, their reported ti,2 is longer and their Cl is reduced for both the R and S epimers as compared with the values obtained for our patients. This difference is most likely the result of the age difference of the two study populations. The exact clinical significance of the individual epimer pharmacokinetics is unknown. The R epimer appears to be twice as active microbiologically in vitro as the S epimer (17) . This difference, combined with the possible tissue diffusion differences between the epimers, needs to be evaluated.
The results of the present investigation suggest that in children of >1 year of age a dose of 50 mg of moxalactam per kg administered every 8 h will result in drug concentrations in serum which exceed the minimal inhibitory concentration for most susceptible pathogens throughout the entire dosing interval (data not shown). The only exceptions to this are some of the susceptible strains of Staphylococcus aureus (minimal inhibitory concentration, 24 ,ug/ml) and Pseudomonas aeruginosa (minimal inhibitory concentration, 216 ,ug/ml). For children between 2 and 5. 
